



Health Promotion  
and Protection

# **Notifiable Diseases in Nova Scotia 2008 Surveillance Report**

## **ACKNOWLEDGEMENTS**

---

The authors wish to gratefully acknowledge the on-going contributions of laboratory staff, public health staff, nurses, and physicians in Nova Scotia without whose diligence in reporting notifiable diseases, surveillance would not be possible.

The assistance of the Information Analysis and Reporting Section of the Office of the Chief Information Officer, Nova Scotia Department of Health in providing census data is also gratefully acknowledged.

For questions regarding this report, contact:

Population Health Assessment and Surveillance  
Nova Scotia Health Promotion and Protection  
Summit Place, 1601 Lower Water Street  
PO Box 487  
Halifax, NS B3J 2R7

Phone: (902) 424-0443

Fax: (902) 424-4716

Email: [surveillancehpp@gov.ns.ca](mailto:surveillancehpp@gov.ns.ca)

# TABLE OF CONTENTS

---

<b>1.0</b>	<b>Introduction .....</b>	<b>1</b>
<b>2.0</b>	<b>Methods .....</b>	<b>2</b>
2.1	Limitations .....	2
<b>3.0</b>	<b>2008 Highlights.....</b>	<b>3</b>
3.1	Notifiable Diseases Among Females and Males in Nova Scotia in 2008 .....	5
3.2	Notifiable Diseases by Age Group in Nova Scotia in 2008.....	5
<b>4.0</b>	<b>Diseases in Nova Scotia by Disease Group.....</b>	<b>7</b>
4.1	Sexually Transmitted and Blood Borne Pathogens .....	7
4.1.1	Chlamydia .....	7
4.1.2	Gonorrhea .....	9
4.1.3	Syphilis .....	9
4.1.4	HIV & AIDS.....	10
4.1.5	Hepatitis B (Acute and Chronic Carrier) .....	10
4.1.6	Hepatitis C .....	10
4.2	Enterics .....	11
4.2.1	Campylobacteriosis .....	11
4.2.2	Salmonellosis .....	12
4.2.3	Giardiasis .....	12
4.2.4	Other Reportable Enteric Conditions .....	12
4.2.5	Outbreaks of Enteric Illness.....	12
4.3	Conditions transmitted by the respiratory route or direct contact .....	13
4.3.1	Influenza Virus.....	13
4.3.2	Invasive Pneumococcal disease .....	14
4.3.3	Invasive Meningococcal Disease .....	14
4.3.4	Invasive Group A Streptococcal Disease .....	14
4.3.5	Tuberculosis .....	14
4.3.6	Methicillin Resistant Staphylococcus Aureus infections (MRSA)...	15
4.3.7	Vancomycin-Resistant Enterococcus .....	15
4.3.8	Other Pathogens .....	15
4.3.9	Outbreaks of Respiratory illness.....	15
4.4	Vaccine Preventable conditions .....	16
4.4.1	Pertussis.....	16
4.4.2	Mumps.....	16
4.4.3	Other Conditions .....	16
4.5	Zoonoses.....	16
4.5.1	Q Fever .....	16
4.5.2	Lyme disease .....	17
4.5.3	Other Conditions .....	17
<b>5.0</b>	<b>References.....</b>	<b>18</b>
<b>6.0</b>	<b>Appendix (See list of Tables) .....</b>	<b>19</b>

## LIST OF TABLES IN APPENDIX

---

	Page
<b>TABLE 1:</b> Notifiable conditions reported in Nova Scotia in 1999-2008: Number of reports and crude rates per 100,000 population.....	20
<b>TABLE 2:</b> Notifiable conditions reported in Capital in 1999-2008: Number of reports and crude rates per 100,000 population.....	21
<b>TABLE 3:</b> Notifiable conditions reported in Western in 1999-2008: Number of reports and crude rates per 100,000 population.....	22
<b>TABLE 4:</b> Notifiable conditions reported in Northern in 1999-2008: Number of reports and crude rates per 100,000 population.....	23
<b>TABLE 5:</b> Notifiable conditions reported in Eastern in 1999-2008: Number of reports and crude rates per 100,000 population.....	24
<b>TABLE 6:</b> Notifiable conditions reported in Nova Scotia in 2008 by shared service area and district .....	25
<b>TABLE 7:</b> Notifiable conditions reported in Nova Scotia in 2008 by month .....	26
<b>TABLE 8:</b> Notifiable conditions reported in Nova Scotia in 2008: Number of reports and age specific rates per 100,000 population ...	27

## 1.0 Introduction

Surveillance has been defined by the US Centers for Disease Control and Prevention (CDC) as “the ongoing, systematic collection, analysis and interpretation of health data essential to the planning, implementation and evaluation of public health practice, closely integrated with the timely dissemination of these data to those who need to know.”<sup>1</sup>

In Canada, surveillance of communicable diseases is supported by provincial legislation that mandates the reporting or notifying of diseases by many individuals and groups within the public health system. The list of notifiable diseases differs by province/territory but the Public Health Agency of Canada provides specific case definitions for those diseases under national surveillance in order to facilitate comparability across jurisdictions.<sup>2</sup>

Reporting of notifiable diseases in Nova Scotia is governed by the provincial *Health Protection Act*.<sup>3</sup> This legislation outlines the responsibilities of public health officials for reporting and managing notifiable diseases within the province. More detailed information regarding the methodology of this report is presented in Section 2.

The purpose of this report is to provide a summary of notifiable diseases reported in Nova Scotia in 2008. The report was compiled by the Population Health Assessment and Surveillance (PHAS) Responsibility Centre, Nova Scotia Department of Health Promotion and Protection (HPP). It includes highlights of notifiable disease data for 2008, examines important trends between 1999-2008 and provides some comparisons with national data. In the Appendix, numbers and rates of notifiable diseases are presented for a 10 year period for the province and by Shared Service Area (SSA), and by month, district, and age group for 2008.

## 2.0 Methods

In Nova Scotia, notifiable communicable diseases are reportable as specified under the *Health Protection Act*. The following persons are required to report cases of notifiable diseases to the Medical Officer of Health<sup>4</sup>:

- physicians
- registered nurses
- medical laboratory technologists
- principal of a public school or operator of a private school
- administrator of an institution (including day care facilities, universities and community colleges)
- employees of Canadian Blood Services

Nova Scotia is composed of nine District Health Authorities (DHAs) which are grouped into four shared service areas (SSA): Western (DHAs 1, 2 and 3), Northern (DHAs 4, 5 and 6), Eastern (DHAs 7 and 8) and Capital (DHA 9).<sup>5</sup> Notifiable disease data is reported to the Nova Scotia Department of Health Promotion and Protection (HPP) by the District Health Authorities. This data is analyzed and reported by HPP. Some data are reported at the SSA level in the report.

Final statistics for Nova Scotia exclude notifications among non-residents and from Nova Scotians diagnosed in another province of Canada. These cases are attributed to the province where the initial positive diagnosis was made. However, cases first diagnosed in Nova Scotia among persons who have acquired their infection outside Canada (prior to migration or associated with travel) are included.

Rates were calculated based on the most currently available population estimates from Statistics Canada as of June 2008. All Canadian data presented throughout the report is from 2006 and was obtained from the Public Health Agency of Canada.<sup>6</sup>

## 2.1 Limitations


It should be noted that the numbers cited in this report reflect only those diseases that are reported to Public Health Services and may under-represent the true number of cases in the population. This is particularly relevant for conditions that may remain asymptomatic (e.g. chlamydia) and those that have a wide clinical spectrum. Persons experiencing severe illness would be more likely to present for medical care and therefore undergo diagnosis (e.g. invasive meningococcal disease).

### 3.0 2008 Highlights


A total of 4372 cases of notifiable diseases were reported in Nova Scotia in 2008. A few selected highlights of these data are presented below:

- Chlamydia:
  - 2033 cases (rate of 218/100,000 population) were reported in 2008, making chlamydia the most frequently reported notifiable disease in Nova Scotia
  - The 15-24 year old age group had the highest rate of chlamydia compared to other age groups (1200/100,000 population)
  - The rate among females was 315/100,000 vs. 117/100,000 for males
  
- Hepatitis C :
  - 281 cases (rate of 30/100,000 population) were reported in 2008
  - The rate among 25-39 year olds was 60/100,000 population
  - The rate among males was almost three times the rate for females (44/100,000 population vs. 17/100,000 population)
  
- Mumps:
  - 5 cases (rate of 0.5/100,000 population) were reported in 2008
  - Only 1 case reported in 2008 was not associated with the most recent outbreak in Nova Scotia
  
- Q Fever:
  - An outbreak was identified in Capital SSA in 2008
  - 17 cases were associated with the outbreak
  
- Gonorrhoea:
  - 143 cases (rate of 15/100,000 population) were reported in 2008
  - The rate in 2008 was significantly higher than the 2007 rate

**Figure 1: Summary of notifiable diseases reported in Nova Scotia by disease category, 2008**



**Figure 2: Summary of notifiable diseases reported in Nova Scotia by disease type, 2008**






### 3.1 Notifiable Diseases Among Females and Males in Nova Scotia in 2008

There was a greater number of cases of notifiable diseases reported among females (n=2562) compared to males (n=1810) in 2008. Chlamydia, MRSA, hepatitis C and influenza were among the top five most frequently reported diseases for both males and females. A summary of the counts of notifiable diseases reported in 2008 for females and males is presented below:



**Figure 3: Summary of notifiable diseases reported in Nova Scotia by sex, 2008**



### 3.2 Notifiable Diseases by Age Group in Nova Scotia in 2008

Variation in age distribution for notifiable diseases is not unexpected. Depending on the disease type, symptoms and mode of transmission, different age groups may be affected. A summary of notifiable diseases by age group in Nova Scotia for 2008 is presented in Figure 4.

**Figure 4: Summary of notifiable diseases reported in Nova Scotia by age group\*, 2008**




\*Five cases of Chlamydia and two cases of Hepatitis C with age unspecified excluded.

## 4.0 Diseases in Nova Scotia by Disease Group

The purpose of this section is to present more detailed information on each category of notifiable diseases in Nova Scotia. Information is presented for: sexually transmitted and blood borne pathogens, enterics, diseases transmitted by the respiratory route or direct contact, zoonoses, and vaccine preventable conditions.

### 4.1 Sexually Transmitted and Blood Borne Pathogens


**Figure 5: Rate per 100,000 population for sexually transmitted and blood borne pathogens in Nova Scotia, 2008**



#### 4.1.1 Chlamydia

Chlamydia was the most frequently reported notifiable disease in Nova Scotia in 2008 (n=2033). The number of cases (and the rate) of chlamydia increased from 1999 to 2008. The largest increase occurred between 2007 and 2008 (Figure 5). The rate of chlamydia in Nova Scotia in 2008 was 218/100,000 population compared to the national 2008 chlamydia rate of 237/100,000 population.<sup>7</sup>

**Figure 6: Trend in the rate of Chlamydia in Nova Scotia, 1999-2008**



As mentioned in Section 3, the 15-24 year age group has the highest number of cases and the highest rate compared to other age groups (1494 cases; rate of 1200/100,000 population). Overall, 73% of all reported cases of chlamydia in 2008 were among youth aged 15-24 years. Also, the rate among females in Nova Scotia is higher compared to that of males (315/100,000 population vs. 117/100,000 population). This is consistent with the Canadian data.<sup>8</sup>

Rates of chlamydia infection were high across all Shared Service Areas, with the highest rate of infection in 2008 reported in Capital (277/100,000 population) followed by Northern (196/100,000 population), Western (184/100,000 population) and Eastern (138/100,000 population).

Increases in reported chlamydia infection rates across Canada coincide with increased sexual risk behaviours and poor knowledge about STI transmission among young people.<sup>8</sup> It is unclear to what extent increased rates may be attributable to more testing, and to the introduction of more sensitive diagnostic testing methods (nucleic acid amplification testing) across Canada in the late 1990s.<sup>9</sup>

Given that a large proportion of males (50%) and females (70%) may not develop acute symptoms (but remain at risk of developing complications), reported cases represent an under-estimate of the true burden of chlamydia infection in the community.


### 4.1.2 Gonorrhoea

Between 1999 and 2008, the rate of gonorrhoea infections fluctuated between a low of 6.2/100,000 population in 2000 to a high of 21.3/100,000 population in 2002. Although the rate of gonorrhoea between 2003 and 2007 remained relatively low and stable, the rate in 2008 was double that in 2007 (15/100,000 population vs. 7.7/100,000 population). Still, the Nova Scotian gonorrhoea rate remains lower than the 2008 Canadian rate of 38/100,000 population.<sup>7</sup>

The 143 cases reported in Nova Scotia in 2008 is twice the number reported in 2007 (72 cases), and while rates are subject to variability due to low case numbers, the rate in 2008 is significantly higher than the previous two years.

Rates of gonorrhoea infection were highest in Capital (26/100,000 population); other SSAs experienced rates below the provincial crude rate. Fifty-eight percent of cases occurred in the 15-24 year age group, and there was no difference in the number of cases for females (n=71) and males (n=72).

**Figure 7: Trend in the rate of Gonorrhoea in Nova Scotia, 1999-2008**



### 4.1.3 Syphilis

Twelve cases of syphilis were reported in Nova Scotia in 2008. This represents a rate of 1.3/100,000 population, which is less than the 2008 Canadian rate of infectious syphilis 4.0/100,000. All cases were greater than 25 years of age.

Rates of syphilis in Nova Scotia ranged from 0/100,000 population to 2.1/100,000 between 1999 and 2008 and were consistently less than the Canadian rate during this time period.

#### **4.1.4 HIV & AIDS**

There were 14 newly diagnosed cases of HIV in Nova Scotia in 2008 (rate of 1.5/100,000 population) bringing the cumulative number of new diagnoses since 1983 (when the first case was reported) to 718.

Of the 201 cases of HIV reported between 1999-2008, 46% of cases (n=92) reported men having sex with men (MSM) as a risk factor, 18% of cases (n=36) reported injection drug use and, additionally, 3% of cases (n=6) reported both risk factors. A total of 54 (27%) individuals diagnosed over the same time period were likely to have acquired their infection through heterosexual contact, of which at least 15 were known to have acquired their infection in a country where HIV is endemic.

Eleven of the 14 cases diagnosed in 2008 were men. MSM was a risk factor for five cases (36%). Sixty-four percent of cases were between the ages of 20-39 years.

One new case of AIDS was reported in 2008, bringing the cumulative reports of AIDS in Nova Scotia to 325.

#### **4.1.5 Hepatitis B (Acute and Chronic Carrier)**

Hepatitis B has been part of the immunization school based program since 1995. The number of reported acute cases of hepatitis B have declined over the decade, from 21 cases in 1999 to 7 cases in 2008. The rate of acute hepatitis B for 2008 was 0.8/100,000 population compared to the 2006 Canadian rate of 2/100,000 population.

There were 14 cases of chronic hepatitis B reported in 2008 (rate of 1.5/100,000 population). The majority were among adults who had acquired their infection in an endemic country prior to living in Nova Scotia or through travel.

#### **4.1.6 Hepatitis C**

Hepatitis C was the third most frequently reported notifiable disease in Nova Scotia in 2008 (281 cases; rate of 30/100,000 population). This is comparable to the 2006 Canadian rate of 31.2/100,000 population. The highest rate of hepatitis C among the SSAs was in Eastern SSA with a rate of 49/100,000 population.


The rate of infection was higher among males than females (44/100,000 population vs. 17/100,000) and in those aged 25-39 (58/100,000 population).

Of the 281 cases of hepatitis C reported in 2008, 138 cases (49%) were lost to follow-up and therefore did not have any available risk factor information. Of the 144 cases that did contain risk factor information, 123 cases (85%) reported injection drug use as a risk factor.

## 4.2 Enterics

There were 451 notifications of enteric pathogens in Nova Scotia in 2008. The most frequently reported enteric infections were campylobacteriosis (n=159), salmonellosis (n=139) and giardiasis (n=107).

**Figure 8: Rate per 100,000 population for enteric diseases in Nova Scotia, 2008**



### 4.2.1 Campylobacteriosis

Campylobacteriosis infections were the most commonly reported enteric pathogen in Nova Scotia in 2008 (159 cases; rate of 17/100,000 population). This rate is less than that for Canada in 2006 which was 25/100,000 population. The highest rate among SSAs occurred in Western SSA with a rate of 25/100,000 population. Seventy-nine percent of cases reported in 2008 were over 25 years of age.

#### **4.2.2 Salmonellosis**

Salmonella infections were the second most frequently reported enteric pathogen in Nova Scotia in 2008 (139 cases; 15/100,000 population). This is reflective of the 2006 Canadian rate of 14/100,000 population. Western SSA reported the highest rate of infection at 20/100,000 population and 70% of all cases in 2008 were reported for adults aged 25 years and older.

#### **4.2.3 Giardiasis**

A total of 107 cases of giardiasis were reported in Nova Scotia in 2008, representing a rate of 11.5/100,000 population. The 2006 Canadian rate of giardiasis was 11.5/100,000 population. 75% of cases were aged 25 years and older.

#### **4.2.4 Other Reportable Enteric Conditions**

The notification rate of other reportable enteric conditions in Nova Scotia in 2008 remained low for all other disease types (<2/100,000 population) and below or similar to the 2006 national rates. The majority of these infections have remained stable over time with the exception of verotoxigenic *E.coli* infections which have declined from a peak of 47 cases in 2000 to 10 cases in 2008; a rate of 1.1/100,000 population. Travel was associated with 17.6% (n=79) of reported enteric infections overall.


#### **4.2.5 Outbreaks of Enteric Illness**

A total of 36 outbreaks of enteric pathogens were reported in Nova Scotia in 2008. Twenty-one of the outbreaks reported, occurred in long term care facilities. Six were reported among non-residential facilities, three were associated with private gatherings and two with food service establishments. Norovirus accounted for 22 of the 36 outbreaks. Other isolated pathogens included salmonella (two outbreaks) and *Clostridium* (one outbreak).



### 4.3 Conditions transmitted by the respiratory route or direct contact

**Figure 9: Rate per 100,000 population for conditions transmitted by the respiratory route or direct contact in Nova Scotia, 2008**



#### 4.3.1 Influenza Virus

In Canada, the influenza season usually begins in November and ends the following April. Influenza infection is very common during the winter with the majority of persons recovering without complications. However, older persons (especially those over 65 years) and those with coexisting medical conditions are more likely to develop complications and in some cases may die from the infections.<sup>9</sup>

A total of 262 laboratory-confirmed infections due to influenza virus were reported during 2008 of which 155 (59%) were influenza A strain and 107 (41%) were influenza B. All but one of those cases was within the 2007/2008 influenza season (roughly September 2007 through August 2008). The overall rate for the calendar year was 28/100,000 population with the highest crude rate reported in Capital SSA (34/100,000 population). Twenty-eight percent of cases of influenza reported in 2008 were children less than 15 years of age and 44% of cases were adults 60 years or older. The highest rate of influenza occurred in infants <1 year of age (rate of 169/100,000 population). This high rate may be partially explained by the greater likelihood of influenza testing among this age group.

More detailed information on influenza can be found at the following website: <http://www.gov.ns.ca/hpp/resources/cdpc-respiratory-diseases.asp>  
This includes the weekly Respiratory Watch report that provides more detailed statistics for influenza in Nova Scotia.

#### ***4.3.2 Invasive Pneumococcal disease***

In 2008, 14 cases of invasive pneumococcal disease were reported which represents a rate of 1.5/100,000 population. This is less than the 2006 Canadian rate of 6.8/100,000 population. Provincially, this is a decline from 2007, when 26 cases were reported for a rate of 2.8/100,000 population. Fifty percent of the cases reported in 2008 were among those 60 years and older, and 8 of the 14 cases were female.

The 7-valent pneumococcal vaccine was introduced as part of the childhood immunization schedule in 2005 for children under one year of age. This supplements the 23 valent vaccine already recommended for adults 65 years of age and over and those at high risk for invasive pneumococcal disease.

#### ***4.3.3 Invasive Meningococcal Disease***

There were 8 cases of invasive meningococcal disease reported in 2008. Four cases were serogroup C, three serogroup B and one unknown. Three of the cases were less than 5 years of age. The overall rate of 0.9/100,000 population in 2008 was similar to the 2006 Canadian rate of 0.5/100,000 population.

In Nova Scotia, meningococcal group C vaccine has been part of the immunization schedule for 12-month-old infants and as a catch-up immunization in the school based program since 2005.

#### ***4.3.4 Invasive Group A Streptococcal Disease***

Sixteen cases of invasive group A streptococcal disease were reported in 2008 (rate of 1.7/100,000 population). This is slightly lower than the 2006 Canadian rate of 2.9/100,000 population. Seventy-five percent of cases (n=12) were 40 years of age or more.

#### ***4.3.5 Tuberculosis***

Four cases of tuberculosis were reported in 2008, representing a rate of 0.4/100,000 population. This is less than the 2006 Canadian rate of 5/100,000 population. All cases reported in 2008 were 25 years of age or older.

#### ***4.3.6 Methicillin Resistant Staphylococcus Aureus infections (MRSA)***

The rate of MRSA in Nova Scotia in 2008 was 109/100,000 population with the highest rate reported in Northern SSA (186/100,000 population).

Older adults, 60 years of age and older, accounted for 75% of all cases reported in the province in 2008. The rate among this age group was 162/100,000 population (n=758) with a slightly higher rate reported among males compared to females (170/100,000 population vs. 155/100,000 population).

Notifications of MRSA have dramatically increased since the condition became notifiable in 2001. 119 cases of MRSA were reported in 2001 compared to 1013 cases in 2008. There has been an increase in testing for MRSA through the establishment of screening programs in hospitals across Nova Scotia over the past decade and positive tests may reflect patients who are not only infected with MRSA but also those who are colonized with MRSA. It is difficult to gauge therefore, the extent to which the increase in the number of reports is due to greater testing vs. a real increase in infections.

#### ***4.3.7 Vancomycin-Resistant Enterococcus***

In 2008, 31 cases of vancomycin-resistant enterococcus were reported in Nova Scotia (rate of 3.3/100,000 population). Seventy-one percent of the cases reported were in those 60 years of age and older.

#### ***4.3.8 Other Pathogens***

There were two cases of group B streptococcal disease of the Newborn in 2008. There were no cases of legionellosis reported in Nova Scotia in 2007 and 2008.

#### ***4.3.9 Outbreaks of Respiratory Illness***

There were 44 outbreaks involving respiratory pathogens reported in Nova Scotia in 2008, 38 of which occurred in long-term care facilities. Influenza virus was the most common pathogen reported (n=22 outbreaks) followed by respiratory syncytial virus (n=5 outbreaks). Thirteen outbreaks were associated with an 'influenza like illness' although no pathogen could be isolated.

## **4.4 Vaccine Preventable conditions**

There were 20 cases of vaccine preventable conditions reported in Nova Scotia in 2008. They are presented in more detail below.

### **4.4.1 Pertussis**

There were 14 cases of cases of pertussis reported in 2008 (rate of 1.5/100,000 population). This was the lowest rate of pertussis reported since 2003 and is comparable to the 2006 Canadian rate of 5.3/100,000 population.

Three cases were reported in infants under 1 year of age (rate 36/100,000 population) with other cases occurring across other age groups.

### **4.4.2 Mumps**

A total of five cases of mumps were reported in Nova Scotia in 2008 (rate 0.5/100,000 population). Four of these cases were associated with the mumps outbreak that began in April 2007 and was declared over in September 2008.

### **4.4.3 Other Conditions**

There was one reported case of invasive *Haemophilus Influenzae* type b in 2008, the first case since 2005.

No cases of tetanus have been reported since 1998; no cases of measles since 2000; and no cases of rubella since 2006.

## **4.5 Zoonoses**

There were 32 cases of zoonoses reported in Nova Scotia in 2008. More detailed information about specific conditions is reported below.

### **4.5.1 Q Fever**

An outbreak of Q fever was identified in the Capital SSA in 2008. A total of 17 cases were reported, and associated with this outbreak. Infected individuals complained of fever, cough, weakness and fatigue and some had evidence of atypical pneumonia on chest x-rays.

#### **4.5.2 Lyme disease**

Thirteen cases of Lyme disease were reported in Nova Scotia in 2008. Ten of these cases acquired the infection in Nova Scotia, one acquired infection outside the province and for two cases the location of acquisition is unknown.

Since 2002, 33 cases of Lyme disease have been reported in Nova Scotia. Twenty-four of these cases acquired infection within Nova Scotia, six acquired infection outside the province and the source was unknown for three cases.

Tick surveillance in Nova Scotia has identified three established areas of the vector for Lyme disease: the Lunenburg area of Lunenburg County, the Admiral's Cove area of Halifax County and the Gunning Cove area of Shelburne County. There is no confirming evidence to suggest that the tick vector for Lyme disease has become established in other parts of the province.

The national case definition for Lyme disease was updated in 2008 to include a "possible" case classification. Four reported cases met this definition in 2008, all with links to the established geographic locations described above.

#### **4.5.3 Other Conditions**

Three adults were reported with toxoplasmosis in 2008 (rate of 0.3/100,000 population) bringing the total number of cases reported in Nova Scotia to six in the past decade. All three had recent exposure to animals.

Two cases of malaria were reported in 2008 (rate of 0.2/100,000 population). Both were acquired in a country endemic for malaria.

Two cases of Creutzfeldt-Jacob Disease were notified in NS in 2008 bringing the total of reported cases over the past decade to 14. All notified cases in Nova Scotia were sporadic and occurred in older adults.

One case of infection with West Nile virus (neurological syndrome) was reported in 2008. This case was exposed to the virus outside of Nova Scotia.

## 5.0 References

1. Centers for Disease Control and Prevention (CDC), January 1988. *Update CDC Surveillance*. Atlanta, GA: CDC.
2. Advisory Committee on Epidemiology and the Division of Disease Surveillance, Bureau of Infectious Diseases, Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. *Case Definitions for Diseases Under National Surveillance*, 2000. Minister of Public Works and Government Services Canada, 2000. Cat. No. H49- 141/2000.
3. Health Protection Act: <http://www.gov.ns.ca/hpp/cdpc/health-protection-act.asp>
4. A Guide to the Health Protection Act and Regulations: [http://www.gov.ns.ca/hpp/publications/Guide\\_HPA\\_05.pdf](http://www.gov.ns.ca/hpp/publications/Guide_HPA_05.pdf)
5. Notifiable Diseases in Nova Scotia Surveillance Report 2007: [http://www.gov.ns.ca/hpp/publications/Annual\\_Report\\_2007.pdf](http://www.gov.ns.ca/hpp/publications/Annual_Report_2007.pdf)
6. PHAC website: <http://www.phac-aspc.gc.ca/surveillance-eng.php>
7. Reported cases of notifiable STI from January 1 to December 31, 2007 and January 1 to December 31, 2008 and corresponding rates for January 1 to December 31, 2007 and 2008: <http://www.phac-aspc.gc.ca/std-mts/stdcases-casmts/cases-cas-08-eng.php>
8. Brief Report on Sexually Transmitted Infections In Canada: 2006: [http://www.phac-aspc.gc.ca/publicat/2008/sti-its/pdf/sti\\_brief-its\\_bref-eng.pdf](http://www.phac-aspc.gc.ca/publicat/2008/sti-its/pdf/sti_brief-its_bref-eng.pdf)
9. Public Health Agency of Canada, Influenza: <http://www.phac-aspc.gc.ca/influenza/index-eng.php>
10. 1998/1999 Canadian Sexually Transmitted Diseases (STD) Surveillance Report. Canada Communicable Disease Report. Vol.26-S6. October 2000.

## 6.0 Appendix (See list of Tables)

**TABLE 1: NOTIFIABLE CONDITIONS REPORTED IN NOVA SCOTIA IN 1999-2008: Number of Reports and Crude Rates per 100,000 population**

CONDITION	1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		All Years	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Enteric</b>																						
Amoebiasis	13	1.4	6	0.6	15	1.6	8	0.9	4	0.4	14	1.5	10	1.1	13	1.4	11	1.2	9	1.0	103	1.1
Campylobacteriosis	163	17.5	173	18.5	171	18.3	201	21.5	140	14.9	150	16.0	125	13.4	132	14.1	133	14.2	159	17.0	1547	16.5
Cryptosporidiosis	8	0.9	6	0.6	10	1.1	8	0.9	6	0.6	9	1.0	18	1.9	9	1.0	13	1.4	11	1.2	98	1.0
Cyclosporiasis	7	0.7	3	0.3	11	1.2	2	0.2	2	0.2	2	0.2	0	0.0	3	0.3	3	0.3	0	0.0	33	0.4
Giardiasis	80	8.6	89	9.5	85	9.1	122	13.1	87	9.3	87	9.3	108	11.5	106	11.3	74	7.9	107	11.5	945	10.1
Hepatitis A	10	1.1	8	0.9	7	0.8	6	0.6	4	0.4	8	0.9	5	0.5	18	1.9	5	0.5	4	0.4	75	0.8
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	1	0.0
Listeriosis	2	0.2	0	0.0	4	0.4	0	0.0	7	0.7	1	0.1	5	0.5	4	0.4	6	0.6	2	0.2	31	0.3
Paralytic Shellfish Poisoning	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	3	0.0
Paratyphoid	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.2	3	0.3	0	0.0	1	0.1	6	0.1
Salmonella	139	14.9	172	18.4	188	20.2	143	15.3	133	14.2	110	11.7	121	12.9	105	11.2	121	13.0	139	14.9	1371	14.7
Shigella	7	0.7	10	1.1	8	0.9	15	1.6	7	0.7	8	0.9	19	2.0	6	0.6	6	0.6	4	0.4	90	1.0
Verotoxigenic E. coli	36	3.9	47	5.0	29	3.1	23	2.5	17	1.8	14	1.5	14	1.5	21	2.2	15	1.6	10	1.1	226	2.4
Yersiniosis	4	0.4	1	0.1	3	0.3	2	0.2	1	0.1	3	0.3	2	0.2	4	0.4	5	0.5	4	0.4	29	0.3
<b>Respiratory and Others</b>																						
Creutzfeldt Jakob Disease	0	0.0	1	0.1	1	0.1	1	0.1	2	0.2	2	0.2	1	0.1	2	0.2	2	0.2	2	0.2	14	0.1
Encephalitis (Viral)	0	0.0	0	0.0	2	0.2	1	0.1	0	0.0	0	0.0	1	0.1	0	0.0	2	0.2	1	0.1	7	0.1
Group A Streptococcal Disease Invasive	3	0.3	5	0.5	8	0.9	17	1.8	20	2.1	20	2.1	26	2.8	16	1.7	25	2.7	16	1.7	156	1.7
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	2	0.2	3	0.0
Influenza (Laboratory Confirmed)	102	10.9	138	14.8	191	20.5	104	11.1	227	24.2	199	21.2	489	52.2	116	12.4	180	19.3	262	28.1	2008	21.5
Legionellosis	2	0.2	1	0.1	3	0.3	1	0.1	0	0.0	0	0.0	2	0.2	1	0.1	0	0.0	0	0.0	10	0.1
Meningitis (Bacterial)	2	0.2	4	0.4	6	0.6	4	0.4	3	0.3	3	0.3	4	0.4	2	0.2	4	0.4	5	0.5	37	0.4
Meningitis (Viral)	1	0.1	4	0.4	11	1.2	9	1.0	2	0.2	1	0.1	6	0.6	6	0.6	14	1.5	3	0.3	57	0.6
Meningococcal Disease Invasive	6	0.6	5	0.5	7	0.8	5	0.5	3	0.3	7	0.7	2	0.2	4	0.4	4	0.4	8	0.9	51	0.5
Methicillin resistant Staphylococcus aureus	43	4.6	86	9.2	119	12.8	193	20.7	374	39.9	417	44.5	759	81.1	849	90.8	951	101.8	1013	108.6	4804	51.4
Pneumococcal Disease Invasive	1	0.1	1	0.1	4	0.4	3	0.3	9	1.0	17	1.8	27	2.9	22	2.4	26	2.8	14	1.5	124	1.3
Tuberculosis	15	1.6	3	0.3	8	0.9	9	1.0	6	0.6	8	0.9	6	0.6	10	1.1	8	0.9	4	0.4	77	0.8
Vancomycin resistant Enterococcus (VRE)	2	0.2	8	0.9	2	0.2	22	2.4	7	0.7	16	1.7	35	3.7	38	4.1	7	0.7	31	3.3	168	1.8
<b>Bloodborne and Sexually Transmitted</b>																						
Chancroid	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Chlamydia	1354	145.0	1405	150.4	1603	171.9	1574	168.4	1552	165.7	1592	169.7	1745	186.4	1762	188.4	1788	191.4	2033	217.9	16408	175.5
Gonorrhoea	63	6.7	58	6.2	86	9.2	199	21.3	118	12.6	122	13.0	104	11.1	99	10.6	72	7.7	143	15.3	1064	11.4
Hepatitis B (acute)	21	2.2	13	1.4	16	1.7	9	1.0	12	1.3	11	1.2	10	1.1	8	0.9	9	1.0	7	0.8	116	1.2
Hepatitis B (chronic)	51	5.5	28	3.0	13	1.4	21	2.2	26	2.8	25	2.7	22	2.4	36	3.9	10	1.1	14	1.5	246	2.6
Hepatitis C	296	31.7	296	31.7	185	19.8	219	23.4	204	21.8	234	24.9	250	26.7	252	27.0	224	24.0	281	30.1	2441	26.1
HIV	26	2.8	16	1.7	14	1.5	16	1.7	19	2.0	33	3.5	22	2.4	23	2.5	18	1.9	14	1.5	201	2.2
Lymphogranuloma	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	1	0.0
Syphilis	4	0.4	3	0.3	0	0.0	7	0.7	15	1.6	20	2.1	15	1.6	8	0.9	9	1.0	12	1.3	93	1.0
<b>Vectorborne and Zoonoses</b>																						
Lyme Disease	0	0.0	0	0.0	0	0.0	2	0.2	0	0.0	6	0.6	2	0.2	4	0.4	6	0.6	13	1.4	33	0.4
Malaria	3	0.3	4	0.4	3	0.3	2	0.2	0	0.0	6	0.6	3	0.3	2	0.2	4	0.4	2	0.2	29	0.3
Q-Fever	3	0.3	0	0.0	3	0.3	3	0.3	0	0.0	2	0.2	5	0.5	3	0.3	4	0.4	17	1.8	40	0.4
Toxoplasmosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.2	1	0.1	3	0.3	6	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	2	0.2	0	0.0	1	0.1	0	0.0	1	0.1	1	0.1	5	0.1
<b>Vaccine Preventable</b>																						
Haemophilus influenzae type b (Hib) Invasive Dis	0	0.0	0	0.0	0	0.0	2	0.2	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	1	0.1	4	0.0
Measles	1	0.1	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.0
Mumps	0	0.0	0	0.0	0	0.0	2	0.2	1	0.1	0	0.0	30	3.2	6	0.6	595	63.7	5	0.5	639	6.8
Pertussis	36	3.9	25	2.7	60	6.4	85	9.1	20	2.1	21	2.2	25	2.7	48	5.1	33	3.5	14	1.5	367	3.9
Rubella	0	0.0	1	0.1	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0	1	0.1	0	0.0	0	0.0	3	0.0
<b>Total</b>	<b>2504</b>	<b>268.1</b>	<b>2622</b>	<b>280.8</b>	<b>2878</b>	<b>308.7</b>	<b>3041</b>	<b>325.4</b>	<b>3030</b>	<b>323.5</b>	<b>3168</b>	<b>337.8</b>	<b>4023</b>	<b>429.8</b>	<b>3745</b>	<b>400.5</b>	<b>4390</b>	<b>469.9</b>	<b>4372</b>	<b>468.5</b>	<b>33773</b>	<b>361.3</b>



**TABLE 2: NOTIFIABLE CONDITIONS REPORTED IN CAPITAL IN 1999-2008: Number of Reports and Crude Rates per 100,000 population**

CONDITION	1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		All Years	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Enteric</b>																						
Amoebiasis	13	3.4	5	1.3	15	3.9	6	1.5	4	1.0	13	3.3	8	2.0	12	3.0	9	2.2	7	1.7	92	2.3
Campylobacteriosis	62	16.2	65	16.8	61	15.7	66	16.8	52	13.1	60	15.0	57	14.2	56	13.9	60	14.8	72	17.7	611	15.4
Cryptosporidiosis	6	1.6	3	0.8	5	1.3	5	1.3	2	0.5	7	1.8	8	2.0	7	1.7	9	2.2	6	1.5	58	1.5
Cyclosporiasis	0	0.0	2	0.5	8	2.1	2	0.5	0	0.0	1	0.3	0	0.0	2	0.5	3	0.7	0	0.0	18	0.5
Giardiasis	51	13.3	58	15.0	42	10.8	69	17.5	49	12.3	62	15.5	65	16.2	67	16.6	37	9.1	62	15.3	562	14.2
Hepatitis A	4	1.0	5	1.3	5	1.3	5	1.3	2	0.5	3	0.8	1	0.2	15	3.7	4	1.0	2	0.5	46	1.2
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.0
Listeriosis	0	0.0	0	0.0	2	0.5	0	0.0	1	0.3	0	0.0	3	0.7	1	0.2	2	0.5	0	0.0	9	0.2
Paralytic Shellfish Poisoning	0	0.0	0	0.0	2	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1
Paratyphoid	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5	3	0.7	0	0.0	1	0.2	6	0.2
Salmonella	59	15.4	69	17.9	62	15.9	63	16.0	45	11.3	49	12.3	45	11.2	59	14.6	52	12.9	67	16.5	570	14.4
Shigella	5	1.3	8	2.1	7	1.8	9	2.3	4	1.0	4	1.0	14	3.5	5	1.2	2	0.5	3	0.7	61	1.5
Verotoxigenic E. coli	15	3.9	31	8.0	10	2.6	11	2.8	7	1.8	0	0.0	5	1.2	7	1.7	5	1.2	6	1.5	97	2.4
Yersiniosis	0	0.0	0	0.0	1	0.3	1	0.3	0	0.0	1	0.3	1	0.2	1	0.2	1	0.2	2	0.5	8	0.2
<b>Respiratory and Others</b>																						
Creutzfeldt Jakob Disease	0	0.0	0	0.0	1	0.3	0	0.0	2	0.5	2	0.5	0	0.0	1	0.2	1	0.2	0	0.0	7	0.2
Encephalitis (Viral)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.0
Group A Streptococcal Disease Invasive	0	0.0	1	0.3	0	0.0	4	1.0	8	2.0	8	2.0	15	3.7	7	1.7	6	1.5	7	1.7	56	1.4
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	2	0.1
Influenza (Laboratory Confirmed)	75	19.6	44	11.4	52	13.4	18	4.6	62	15.6	90	22.5	139	34.7	51	12.6	61	15.1	138	34.0	730	18.4
Legionellosis	0	0.0	0	0.0	1	0.3	1	0.3	0	0.0	0	0.0	2	0.5	1	0.2	0	0.0	0	0.0	5	0.1
Meningitis (Bacterial)	0	0.0	2	0.5	0	0.0	1	0.3	1	0.3	0	0.0	0	0.0	0	0.0	3	0.7	1	0.2	9	0.2
Meningitis (Viral)	0	0.0	1	0.3	1	0.3	2	0.5	2	0.5	1	0.3	4	1.0	4	1.0	10	2.5	2	0.5	27	0.7
Meningococcal Disease Invasive	3	0.8	3	0.8	4	1.0	2	0.5	1	0.3	4	1.0	1	0.2	2	0.5	1	0.2	5	1.2	26	0.7
Methicillin resistant Staphylococcus aureus	21	5.5	40	10.4	64	16.5	110	27.9	270	68.0	303	75.8	361	90.1	377	93.4	374	92.5	304	74.8	2224	56.1
Pneumococcal Disease Invasive	0	0.0	0	0.0	3	0.8	3	0.8	7	1.8	12	3.0	24	6.0	16	4.0	20	4.9	6	1.5	91	2.3
Tuberculosis	11	2.9	1	0.3	5	1.3	6	1.5	5	1.3	7	1.8	6	1.5	8	2.0	5	1.2	2	0.5	56	1.4
Vancomycin resistant Enterococcus (VRE)	0	0.0	6	1.6	1	0.3	5	1.3	5	1.3	7	1.8	20	5.0	36	8.9	4	1.0	13	3.2	97	2.4
<b>Bloodborne and Sexually Transmitted</b>																						
Chancroid	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Chlamydia	852	222.5	889	230.2	986	253.5	967	245.5	844	212.5	814	203.7	1028	256.4	1040	257.7	1011	249.9	1125	276.8	9556	241.1
Gonorrhoea	57	14.9	43	11.1	74	19.0	178	45.2	104	26.2	103	25.8	89	22.2	77	19.1	62	15.3	105	25.8	892	22.5
Hepatitis B (acute)	5	1.3	7	1.8	7	1.8	4	1.0	7	1.8	5	1.3	5	1.2	1	0.2	1	0.2	0	0.0	42	1.1
Hepatitis B (chronic)	33	8.6	28	7.3	12	3.1	20	5.1	25	6.3	24	6.0	19	4.7	36	8.9	8	2.0	11	2.7	216	5.4
Hepatitis C	159	41.5	183	47.4	97	24.9	131	33.3	104	26.2	116	29.0	95	23.7	74	18.3	72	17.8	105	25.8	1136	28.7
HIV	22	5.7	15	3.9	11	2.8	14	3.6	13	3.3	30	7.5	18	4.5	20	5.0	13	3.2	10	2.5	166	4.2
Lymphogranuloma	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.0
Syphilis	3	0.8	2	0.5	0	0.0	3	0.8	9	2.3	19	4.8	10	2.5	3	0.7	8	2.0	8	2.0	65	1.6
<b>Vectorborne and Zoonoses</b>																						
Lyme Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.5	0	0.0	0	0.0	1	0.2	5	1.2	8	0.2
Malaria	2	0.5	3	0.8	2	0.5	2	0.5	0	0.0	5	1.3	3	0.7	1	0.2	4	1.0	2	0.5	24	0.6
Q-Fever	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.7	1	0.2	1	0.2	17	4.2	23	0.6
Toxoplasmosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	2	0.5	3	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
<b>Vaccine Preventable</b>																						
Haemophilus influenzae type b (Hib) Invasive Disease	0	0.0	0	0.0	0	0.0	1	0.3	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2	3	0.1
Measles	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	29	7.2	5	1.2	483	119.4	4	1.0	521	13.1
Pertussis	16	4.2	19	4.9	39	10.0	50	12.7	13	3.3	15	3.8	18	4.5	35	8.7	17	4.2	10	2.5	232	5.9
Rubella	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.0
<b>Total</b>	<b>1476</b>	<b>385.5</b>	<b>1534</b>	<b>397.3</b>	<b>1580</b>	<b>406.2</b>	<b>1759</b>	<b>446.6</b>	<b>1649</b>	<b>415.2</b>	<b>1768</b>	<b>442.3</b>	<b>2099</b>	<b>523.6</b>	<b>2034</b>	<b>503.9</b>	<b>2351</b>	<b>581.2</b>	<b>2114</b>	<b>520.2</b>	<b>18364</b>	<b>463.3</b>

**TABLE 3: NOTIFIABLE CONDITIONS REPORTED IN WESTERN IN 1999-2008: Number of Reports and Crude Rates per 100,000 population**

CONDITION	1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		All Years	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate				
<b>Enteric</b>																						
Amoebiasis	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	2	1.0	1	0.5	1	0.5	1	0.5	6	0.3
Campylobacteriosis	48	22.9	51	24.4	65	31.3	68	32.8	48	23.2	50	24.2	34	16.5	42	20.5	44	21.5	50	24.6	500	24.2
Cryptosporidiosis	1	0.5	0	0.0	1	0.5	1	0.5	2	1.0	2	1.0	0	0.0	0	0.0	0	0.0	1	0.5	8	0.4
Cyclosporiasis	0	0.0	1	0.5	3	1.4	0	0.0	2	1.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.3
Giardiasis	19	9.1	16	7.7	14	6.7	19	9.2	16	7.7	8	3.9	17	8.2	13	6.3	14	6.8	22	10.8	158	7.6
Hepatitis A	1	0.5	3	1.4	0	0.0	1	0.5	0	0.0	1	0.5	2	1.0	1	0.5	1	0.5	0	0.0	10	0.5
Listeriosis	0	0.0	0	0.0	1	0.5	0	0.0	4	1.9	1	0.5	0	0.0	3	1.5	2	1.0	0	0.0	11	0.5
Paralytic Shellfish Poisoning	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	1	0.0
Salmonella	26	12.4	31	14.8	75	36.1	36	17.4	61	29.4	39	18.9	40	19.4	14	6.8	27	13.2	40	19.7	389	18.8
Shigella	2	1.0	1	0.5	1	0.5	3	1.4	2	1.0	2	1.0	2	1.0	0	0.0	1	0.5	1	0.5	15	0.7
Verotoxigenic E. coli	7	3.3	4	1.9	3	1.4	5	2.4	2	1.0	6	2.9	2	1.0	4	2.0	6	2.9	3	1.5	42	2.0
Yersiniosis	0	0.0	1	0.5	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	2	1.0	2	1.0	1	0.5	7	0.3
<b>Respiratory and Others</b>																						
Creutzfeldt Jakob Disease	0	0.0	1	0.5	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	3	0.1
Encephalitis (Viral)	0	0.0	0	0.0	2	1.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	2	1.0	0	0.0	5	0.2
Group A Streptococcal Disease Invasive	0	0.0	2	1.0	0	0.0	0	0.0	0	0.0	8	3.9	5	2.4	1	0.5	7	3.4	3	1.5	26	1.3
Influenza (Laboratory Confirmed)	13	6.2	33	15.8	65	31.3	25	12.1	93	44.9	21	10.2	144	69.9	28	13.7	49	24.0	43	21.1	514	24.9
Legionellosis	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
Meningitis (Bacterial)	0	0.0	1	0.5	1	0.5	1	0.5	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	4	0.2
Meningitis (Viral)	1	0.5	1	0.5	4	1.9	3	1.4	0	0.0	0	0.0	0	0.0	2	1.0	2	1.0	1	0.5	14	0.7
Meningococcal Disease Invasive	2	1.0	1	0.5	0	0.0	1	0.5	1	0.5	0	0.0	0	0.0	1	0.5	1	0.5	2	1.0	9	0.4
Methicillin resistant Staphylococcus aureus	3	1.4	5	2.4	7	3.4	19	9.2	48	23.2	58	28.0	148	71.8	146	71.3	239	116.9	304	149.4	977	47.3
Pneumococcal Disease Invasive	1	0.5	1	0.5	1	0.5	0	0.0	0	0.0	5	2.4	3	1.5	3	1.5	1	0.5	2	1.0	17	0.8
Tuberculosis	3	1.4	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	4	0.2
Vancomycin resistant Enterococcus (VRE)	0	0.0	1	0.5	1	0.5	0	0.0	0	0.0	0	0.0	4	1.9	0	0.0	0	0.0	3	1.5	9	0.4
<b>Bloodborne and Sexually Transmitted</b>																						
Chlamydia	176	83.9	216	103.3	291	139.9	244	117.7	368	177.6	336	162.5	297	144.1	290	141.5	324	158.5	375	184.3	2917	141.1
Gonorrhea	5	2.4	12	5.7	4	1.9	9	4.3	4	1.9	11	5.3	7	3.4	16	7.8	4	2.0	14	6.9	86	4.2
Hepatitis B (acute)	5	2.4	1	0.5	3	1.4	0	0.0	1	0.5	2	1.0	1	0.5	5	2.4	0	0.0	1	0.5	19	0.9
Hepatitis B (chronic)	18	8.6	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	1	0.5	20	1.0
Hepatitis C	25	11.9	23	11.0	12	5.8	15	7.2	18	8.7	13	6.3	10	4.9	27	13.2	17	8.3	12	5.9	172	8.3
HIV	1	0.5	1	0.5	0	0.0	1	0.5	2	1.0	0	0.0	1	0.5	2	1.0	2	1.0	0	0.0	10	0.5
Syphilis	0	0.0	1	0.5	0	0.0	0	0.0	3	1.4	0	0.0	1	0.5	3	1.5	0	0.0	1	0.5	9	0.4
<b>Vectorborne and Zoonoses</b>																						
Lyme Disease	0	0.0	0	0.0	0	0.0	2	1.0	0	0.0	2	1.0	1	0.5	4	2.0	4	2.0	7	3.4	20	1.0
Malaria	0	0.0	1	0.5	1	0.5	0	0.0	0	0.0	1	0.5	0	0.0	1	0.5	0	0.0	0	0.0	4	0.2
Q-Fever	2	1.0	0	0.0	1	0.5	3	1.4	0	0.0	2	1.0	1	0.5	1	0.5	2	1.0	0	0.0	12	0.6
Toxoplasmosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	1	0.5	1	0.5	3	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	1	0.0
<b>Vaccine Preventable</b>																						
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	53	25.9	1	0.5	54	2.6
Pertussis	5	2.4	1	0.5	11	5.3	25	12.1	2	1.0	4	1.9	2	1.0	0	0.0	8	3.9	1	0.5	59	2.9
<b>Total</b>	<b>365</b>	<b>173.9</b>	<b>411</b>	<b>196.6</b>	<b>567</b>	<b>272.7</b>	<b>483</b>	<b>232.9</b>	<b>677</b>	<b>326.7</b>	<b>574</b>	<b>277.6</b>	<b>727</b>	<b>352.7</b>	<b>613</b>	<b>299.2</b>	<b>814</b>	<b>398.2</b>	<b>891</b>	<b>437.9</b>	<b>6122</b>	<b>296.2</b>

**TABLE 4: NOTIFIABLE CONDITIONS REPORTED IN NORTHERN IN 1999-2008: Number of Reports and Crude Rates per 100,000 population**

CONDITION	1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		All Years	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Enteric</b>																						
Amoebiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Campylobacteriosis	23	14.8	33	21.3	21	13.6	34	22.1	19	12.4	25	16.3	17	11.1	22	14.4	14	9.2	20	13.2	228	14.9
Cryptosporidiosis	0	0.0	2	1.3	1	0.6	2	1.3	1	0.7	0	0.0	3	2.0	1	0.7	1	0.7	1	0.7	12	0.8
Cyclosporiasis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Giardiasis	4	2.6	9	5.8	17	11.0	14	9.1	10	6.5	5	3.3	9	5.9	6	3.9	9	5.9	11	7.3	94	6.1
Hepatitis A	2	1.3	0	0.0	1	0.6	0	0.0	0	0.0	4	2.6	0	0.0	0	0.0	0	0.0	1	0.7	8	0.5
Listeriosis	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	2	1.3	2	1.3	6	0.4
Salmonella	17	11.0	19	12.3	26	16.9	22	14.3	10	6.5	2	1.3	14	9.1	15	9.8	19	12.5	14	9.3	158	10.3
Shigella	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	2	1.3	2	1.3	0	0.0	0	0.0	0	0.0	5	0.3
Verotoxigenic E. coli	2	1.3	4	2.6	10	6.5	3	2.0	4	2.6	5	3.3	7	4.6	10	6.6	4	2.6	1	0.7	50	3.3
Yersiniosis	0	0.0	0	0.0	2	1.3	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	1	0.7	4	0.3
<b>Respiratory and Others</b>																						
Creutzfeldt Jakob Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	2	1.3	3	0.2
Encephalitis (Viral)	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Group A Streptococcal Disease Invasive	1	0.6	0	0.0	2	1.3	1	0.7	2	1.3	1	0.7	4	2.6	2	1.3	5	3.3	3	2.0	21	1.4
Influenza (Laboratory Confirmed)	10	6.5	13	8.4	12	7.8	16	10.4	32	20.8	26	16.9	46	30.1	7	4.6	23	15.2	46	30.4	231	15.1
Legionellosis	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Meningitis (Bacterial)	0	0.0	1	0.6	2	1.3	1	0.7	0	0.0	1	0.7	1	0.7	0	0.0	1	0.7	3	2.0	10	0.7
Meningitis (Viral)	0	0.0	1	0.6	1	0.6	3	2.0	0	0.0	0	0.0	2	1.3	0	0.0	2	1.3	0	0.0	9	0.6
Meningococcal Disease Invasive	0	0.0	1	0.6	2	1.3	0	0.0	0	0.0	3	2.0	1	0.7	0	0.0	2	1.3	0	0.0	9	0.6
Methicillin resistant Staphylococcus aureus	6	3.9	16	10.3	14	9.1	19	12.4	20	13.0	31	20.2	175	114.3	211	138.4	221	145.6	282	186.5	995	64.9
Pneumococcal Disease Invasive	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	1	0.7	2	1.3	1	0.7	5	0.3
Tuberculosis	0	0.0	1	0.6	0	0.0	2	1.3	1	0.7	0	0.0	0	0.0	2	1.3	2	1.3	1	0.7	9	0.6
Vancomycin resistant Enterococcus (VRE)	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	3	2.0	2	1.3	1	0.7	5	3.3	12	0.8
<b>Bloodborne and Sexually Transmitted</b>																						
Chlamydia	192	123.9	176	113.7	171	111.1	179	116.5	208	135.4	268	174.5	198	129.4	206	135.1	240	158.1	296	195.8	2134	139.2
Gonorrhoea	1	0.6	3	1.9	5	3.2	10	6.5	9	5.9	4	2.6	5	3.3	2	1.3	4	2.6	19	12.6	62	4.0
Hepatitis B (acute)	7	4.5	3	1.9	6	3.9	5	3.3	3	2.0	3	2.0	2	1.3	1	0.7	3	2.0	0	0.0	33	2.2
Hepatitis B (chronic)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1
Hepatitis C	55	35.5	42	27.1	41	26.6	43	28.0	35	22.8	51	33.2	63	41.2	71	46.6	65	42.8	78	51.6	544	35.5
HIV	2	1.3	0	0.0	1	0.6	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	2	1.3	6	0.4
Syphilis	0	0.0	0	0.0	0	0.0	2	1.3	1	0.7	1	0.7	1	0.7	1	0.7	1	0.7	1	0.7	8	0.5
<b>Vectorborne and Zoonoses</b>																						
Lyme Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	1	0.7	2	0.1
Q-Fever	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	1	0.1
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	1	0.1
<b>Vaccine Preventable</b>																						
Haemophilus influenzae type b (Hib) Invasive Disease	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Measles	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.7	0	0.0	19	12.5	0	0.0	20	1.3
Pertussis	7	4.5	1	0.6	4	2.6	4	2.6	2	1.3	0	0.0	0	0.0	5	3.3	5	3.3	1	0.7	29	1.9
<b>Total</b>	<b>331</b>	<b>213.5</b>	<b>328</b>	<b>212.0</b>	<b>339</b>	<b>220.2</b>	<b>362</b>	<b>235.6</b>	<b>358</b>	<b>233.0</b>	<b>436</b>	<b>284.0</b>	<b>556</b>	<b>363.2</b>	<b>566</b>	<b>371.3</b>	<b>646</b>	<b>425.6</b>	<b>795</b>	<b>525.9</b>	<b>4717</b>	<b>307.7</b>

**TABLE 5: NOTIFIABLE CONDITIONS REPORTED IN EASTERN IN 1999-2008: Number of Reports and Crude Rates per 100,000 population**

CONDITION	1999		2000		2001		2002		2003		2004		2005		2006		2007		2008		All Years	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Enteric</b>																						
Amoebiasis	0	0.0	0	0.0	0	0.0	2	1.1	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	1	0.6	4	0.2
Campylobacteriosis	30	16.1	24	13.0	24	13.2	33	18.4	21	11.8	15	8.4	17	9.7	12	6.9	15	8.6	17	9.9	208	11.7
Cryptosporidiosis	1	0.5	1	0.5	3	1.7	0	0.0	1	0.6	0	0.0	7	4.0	1	0.6	3	1.7	3	1.7	20	1.1
Cyclosporiasis	7	3.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	8	0.4
Giardiasis	6	3.2	6	3.3	12	6.6	20	11.1	12	6.7	12	6.7	17	9.7	20	11.5	14	8.1	12	7.0	131	7.3
Hepatitis A	3	1.6	0	0.0	1	0.6	0	0.0	2	1.1	0	0.0	2	1.1	2	1.1	0	0.0	1	0.6	11	0.6
Listeriosis	1	0.5	0	0.0	1	0.6	0	0.0	2	1.1	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	5	0.3
Salmonella	37	19.9	53	28.8	25	13.8	22	12.2	17	9.5	20	11.2	22	12.5	17	9.8	23	13.2	18	10.5	254	14.2
Shigella	0	0.0	0	0.0	0	0.0	3	1.7	1	0.6	0	0.0	1	0.6	1	0.6	3	1.7	0	0.0	9	0.5
Verotoxigenic E. coli	12	6.4	8	4.3	6	3.3	4	2.2	4	2.2	3	1.7	0	0.0	0	0.0	0	0.0	0	0.0	37	2.1
Yersiniosis	4	2.1	0	0.0	0	0.0	0	0.0	1	0.6	2	1.1	1	0.6	0	0.0	2	1.2	0	0.0	10	0.6
<b>Respiratory and Others</b>																						
Creutzfeldt Jakob Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	1	0.1
Group A Streptococcal Disease Invasive	2	1.1	2	1.1	6	3.3	12	6.7	10	5.6	3	1.7	2	1.1	6	3.4	7	4.0	3	1.7	53	3.0
Group B Streptococcal Disease of the Newborn	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	1	0.1
Influenza (Laboratory Confirmed)	4	2.1	48	26.1	62	34.2	45	25.0	40	22.4	62	34.8	160	90.9	30	17.2	47	27.1	35	20.3	533	29.9
Legionellosis	0	0.0	1	0.5	2	1.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.2
Meningitis (Bacterial)	2	1.1	0	0.0	3	1.7	1	0.6	2	1.1	1	0.6	3	1.7	1	0.6	0	0.0	1	0.6	14	0.8
Meningitis (Viral)	0	0.0	1	0.5	5	2.8	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	7	0.4
Meningococcal Disease Invasive	1	0.5	0	0.0	1	0.6	2	1.1	1	0.6	0	0.0	0	0.0	1	0.6	0	0.0	1	0.6	7	0.4
Methicillin resistant Staphylococcus aureus	13	7.0	25	13.6	34	18.7	45	25.0	36	20.2	25	14.1	75	42.6	115	66.1	117	67.4	123	71.5	608	34.1
Pneumococcal Disease Invasive	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	2	1.1	3	1.7	5	2.9	11	0.6
Tuberculosis	1	0.5	1	0.5	3	1.7	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	1	0.6	8	0.4
Vancomycin resistant Enterococcus (VRE)	2	1.1	0	0.0	0	0.0	17	9.5	2	1.1	9	5.1	8	4.5	0	0.0	2	1.2	10	5.8	50	2.8
<b>Bloodborne and Sexually Transmitted</b>																						
Chlamydia	134	72.0	124	67.4	155	85.4	184	102.4	132	74.0	174	97.8	222	126.2	226	129.8	213	122.7	237	137.7	1801	101.0
Gonorrhea	0	0.0	0	0.0	3	1.7	2	1.1	1	0.6	4	2.2	3	1.7	4	2.3	2	1.2	5	2.9	24	1.3
Hepatitis B (acute)	4	2.1	2	1.1	0	0.0	0	0.0	1	0.6	1	0.6	2	1.1	1	0.6	5	2.9	6	3.5	22	1.2
Hepatitis B (chronic)	0	0.0	0	0.0	1	0.6	1	0.6	1	0.6	0	0.0	3	1.7	0	0.0	2	1.2	0	0.0	8	0.4
Hepatitis C	56	30.1	48	26.1	35	19.3	30	16.7	47	26.3	54	30.3	82	46.6	80	46.0	70	40.3	85	49.4	587	32.9
HIV	1	0.5	0	0.0	2	1.1	1	0.6	4	2.2	2	1.1	3	1.7	1	0.6	3	1.7	2	1.2	19	1.1
Syphilis	1	0.5	0	0.0	0	0.0	2	1.1	2	1.1	0	0.0	3	1.7	1	0.6	0	0.0	2	1.2	11	0.6
<b>Vectorborne and Zoonoses</b>																						
Lyme Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	1	0.6	0	0.0	1	0.6	0	0.0	3	0.2
Malaria	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Q-Fever	0	0.0	0	0.0	2	1.1	0	0.0	0	0.0	0	0.0	1	0.6	1	0.6	0	0.0	0	0.0	4	0.2
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	2	0.1
<b>Vaccine Preventable</b>																						
Mumps	0	0.0	0	0.0	0	0.0	2	1.1	1	0.6	0	0.0	0	0.0	1	0.6	40	23.0	0	0.0	44	2.5
Pertussis	8	4.3	4	2.2	6	3.3	6	3.3	3	1.7	2	1.1	5	2.8	8	4.6	3	1.7	2	1.2	47	2.6
Rubella	0	0.0	1	0.5	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1
<b>Total</b>	<b>331</b>	<b>177.8</b>	<b>349</b>	<b>189.7</b>	<b>392</b>	<b>216.0</b>	<b>437</b>	<b>243.2</b>	<b>346</b>	<b>193.9</b>	<b>390</b>	<b>219.2</b>	<b>641</b>	<b>364.4</b>	<b>532</b>	<b>305.6</b>	<b>579</b>	<b>333.5</b>	<b>571</b>	<b>331.9</b>	<b>4568</b>	<b>256.1</b>

TABLE 6: NOTIFIABLE CONDITIONS REPORTED IN NOVA SCOTIA IN 2008 BY SHARED SERVICE AREA AND DISTRICT

CONDITION	Western				Northern				Eastern			Capital	Total
	DHA 01	DHA 02	DHA 03	Total	DHA 04	DHA 05	DHA 06	Total	DHA 07	DHA 08	Total	DHA 09	
<b>Enteric</b>													
Amoebiasis	0	0	0	0	0	0	0	0	1	0	1	7	9*
Campylobacteriosis	12	15	23	50	11	5	4	20	6	11	17	72	159
Cryptosporidiosis	1	0	0	1	1	0	0	1	2	1	3	6	11
Giardiasis	12	2	8	22	7	3	1	11	6	6	12	62	107
Hepatitis A	0	0	0	0	0	1	0	1	0	1	1	2	4
Hepatitis E	0	0	0	0	0	0	0	0	0	0	0	1	1
Listeriosis	0	0	0	0	1	1	0	2	0	0	0	0	2
Paratyphoid	0	0	0	0	0	0	0	0	0	0	0	1	1
Salmonella	4	19	17	40	6	6	2	14	5	13	18	67	139
Shigella	0	0	1	1	0	0	0	0	0	0	0	3	4
Verotoxigenic E. coli	1	1	1	3	0	0	1	1	0	0	0	6	10
Yersiniosis	0	1	0	1	1	0	0	1	0	0	0	2	4
<b>Respiratory and Direct Contact</b>													
Creutzfeldt Jakob Disease	0	0	0	0	1	0	1	2	0	0	0	0	2
Encephalitis (Viral)	0	0	0	0	0	0	0	0	0	0	0	1	1
Group A Streptococcal Disease Invasive	1	1	1	3	2	1	0	3	0	3	3	7	16
Group B Streptococcal Disease of the Newb	0	0	0	0	0	0	0	0	0	1	1	1	2
Influenza (Laboratory Confirmed)	9	23	11	43	18	8	20	46	14	21	35	138	262
Meningitis (Bacterial)	0	0	0	0	1	2	0	3	0	1	1	1	5
Meningitis (Viral)	1	0	0	1	0	0	0	0	0	0	0	2	3
Meningococcal Disease Invasive	2	0	0	2	0	0	0	0	0	1	1	5	8
Methicillin resistant Staphylococcus aureus (	133	118	53	304	136	107	39	282	22	101	123	304	1013
Pneumococcal Disease Invasive	0	1	1	2	1	0	0	1	0	5	5	6	14
Tuberculosis	0	0	0	0	0	1	0	1	0	1	1	2	4
Vancomycin resistant Enterococcus (VRE)	3	0	0	3	2	1	2	5	3	7	10	13	31
<b>Bloodborne and Sexually Transmitted</b>													
Chlamydia	70	109	196	375	179	75	42	296	69	168	237	1125	2033
Gonorrhoea	9	2	3	14	16	1	2	19	2	3	5	105	143
Hepatitis B (acute)	0	0	1	1	0	0	0	0	0	6	6	0	7
Hepatitis B (chronic)	0	0	1	1	1	0	1	2	0	0	0	11	14
Hepatitis C	3	2	7	12	23	51	4	78	11	74	85	105	281*
HIV	1	0	0	1	3	0	0	3	1	1	2	8	14
Syphilis	0	1	0	1	1	0	0	1	1	1	2	8	12
<b>Vectorborne and Zoonoses</b>													
Lyme Disease	7	0	0	7	1	0	0	1	0	0	0	5	13
Malaria	0	0	0	0	0	0	0	0	0	0	0	2	2
Q-Fever	0	0	0	0	0	0	0	0	0	0	0	17	17
Toxoplasmosis	0	1	0	1	0	0	0	0	0	0	0	2	3
West Nile Virus	0	0	0	0	1	0	0	1	0	0	0	0	1
<b>Vaccine Preventable</b>													
Haemophilus influenza type b (Hib) Invasive	0	0	0	0	0	0	0	0	0	0	0	1	1
Mumps	0	0	1	1	0	0	0	0	0	0	0	4	5
Pertussis	0	0	1	1	1	0	0	1	2	0	2	10	14
<b>TOTAL</b>	<b>269</b>	<b>296</b>	<b>326</b>	<b>891</b>	<b>414</b>	<b>263</b>	<b>119</b>	<b>796</b>	<b>145</b>	<b>426</b>	<b>571</b>	<b>2112</b>	<b>4372</b>

\*One case with unknown DHA.

TABLE 7: NOTIFIABLE CONDITIONS REPORTED IN NOVA SCOTIA IN 2008 BY MONTH

CONDITION	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	Total
<b>Enteric</b>													
Amoebiasis	2	3	2	0	1	0	1	0	0	0	0	0	9
Campylobacteriosis	8	5	4	14	12	18	16	24	19	17	11	11	159
Cryptosporidiosis	0	0	0	1	0	0	2	4	3	1	0	0	11
Giardiasis	5	11	12	2	8	7	11	9	15	20	6	1	107
Hepatitis A	0	0	0	1	0	0	2	0	1	0	0	0	4
Hepatitis E	0	0	0	0	0	1	0	0	0	0	0	0	1
Listeriosis	0	0	0	0	0	0	0	1	0	1	0	0	2
Paratyphoid	0	1	0	0	0	0	0	0	0	0	0	0	1
Salmonella	7	7	17	14	8	11	17	22	13	11	6	6	139
Shigella	0	0	0	0	1	0	1	1	0	0	0	1	4
Verotoxigenic E. coli	1	0	0	0	0	2	1	3	1	2	0	0	10
Yersiniosis	0	0	1	0	0	0	1	0	2	0	0	0	4
<b>Respiratory and Direct Contact</b>													
Creutzfeldt Jakob Disease	0	0	0	0	0	0	0	2	0	0	0	0	2
Encephalitis (Viral)	1	0	0	0	0	0	0	0	0	0	0	0	1
Group A Streptococcal Disease Invasive	2	1	1	3	4	1	0	1	0	1	0	2	16
Group B Streptococcal Disease of the Newborn	0	0	1	0	0	0	0	1	0	0	0	0	2
Influenza (Laboratory Confirmed)	2	17	80	144	18	0	0	0	1	0	0	0	262
Meningitis (other Bacterial)	1	0	0	1	0	0	0	0	0	0	1	2	5
Meningitis (Viral)	0	1	0	0	0	0	0	1	0	0	0	1	3
Meningococcal Disease Invasive	1	0	0	1	0	0	0	1	1	2	1	1	8
Methicillin resistant Staphylococcus aureus (MRSA)	96	64	72	81	77	76	108	92	79	77	108	83	1013
Pneumococcal Disease Invasive	2	2	3	1	0	0	1	1	1	2	0	1	14
Tuberculosis	0	0	0	0	1	0	1	0	0	0	0	2	4
Vancomycin resistant Enterococcus (VRE)	2	1	2	1	3	2	0	1	3	0	3	13	31
<b>Bloodborne and Sexually Transmitted</b>													
Chlamydia	147	184	167	161	155	158	150	184	172	199	173	182	2033*
Gonorrhoea	10	12	12	8	8	9	15	8	25	12	9	15	143
Hepatitis B (acute)	0	1	1	2	1	0	0	1	0	1	0	0	7
Hepatitis B (chronic)	2	2	3	1	1	2	1	0	0	0	0	2	14
Hepatitis C	25	25	16	30	27	29	13	22	24	22	18	27	281*
HIV	1	1	1	2	0	2	0	3	0	1	0	3	14
Syphilis	3	0	0	0	0	1	1	0	1	1	4	1	12
<b>Vectorborne and Zoonoses</b>													
Lyme Disease	0	0	0	0	1	2	4	2	1	2	0	1	13
Malaria	0	1	0	0	0	0	0	1	0	0	0	0	2
Q-Fever	0	0	0	0	0	0	0	14	3	0	0	0	17
Toxoplasmosis	0	0	0	1	0	0	0	0	0	1	0	1	3
West Nile Virus	0	0	0	0	0	0	0	0	0	1	0	0	1
<b>Vaccine Preventable</b>													
Haemophilus influenzae type b (Hib) Invasive Diseases	0	0	1	0	0	0	0	0	0	0	0	0	1
Mumps	0	1	1	1	1	0	0	0	0	0	1	0	5
Pertussis	1	1	0	0	0	1	0	3	2	4	2	0	14
<b>Total</b>	<b>319</b>	<b>341</b>	<b>397</b>	<b>470</b>	<b>327</b>	<b>322</b>	<b>346</b>	<b>402</b>	<b>367</b>	<b>378</b>	<b>343</b>	<b>356</b>	<b>4372</b>

\*One case chlamydia and three cases Hepatitis C with month unspecified.

TABLE 8: NOTIFIABLE CONDITIONS REPORTED IN NOVA SCOTIA IN 2008: Number of Reports and Age Specific Rates per 100,000 population

CONDITION	Under 1		1-4		5-14		15-24		25-39		40-59		+60		All Ages	Ave. Rate
	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate	N	Rate		
<b>Enteric</b>																
Amoebiasis	0	0.0	0	0.0	0	0.0	1	0.8	4	2.3	3	1.0	1	0.5	9	1.0
Campylobacteriosis	0	0.0	5	14.7	6	6.1	22	17.7	33	18.6	58	20.0	35	17.4	159	17.0
Cryptosporidiosis	0	0.0	1	2.9	0	0.0	4	3.2	3	1.7	3	1.0	0	0.0	11	1.2
Giardiasis	0	0.0	5	14.7	9	9.2	13	10.4	26	14.7	36	12.4	18	8.9	107	11.5
Hepatitis A	0	0.0	0	0.0	0	0.0	1	0.8	0	0.0	2	0.7	1	0.5	4	0.4
Hepatitis E	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	1	0.1
Listeriosis	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.3	1	0.5	2	0.2
Paratyphoid	0	0.0	1	2.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.1
Salmonella	2	24.1	8	23.6	9	9.2	23	18.5	28	15.8	36	12.4	33	16.4	139	14.9
Shigella	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	1.4	0	0.0	4	0.4
Verotoxigenic E. coli	0	0.0	0	0.0	0	0.0	3	2.4	2	1.1	1	0.3	4	2.0	10	1.1
Yersiniosis	0	0.0	0	0.0	0	0.0	1	0.8	1	0.6	1	0.3	1	0.5	4	0.4
<b>Respiratory and Others</b>																
Creutzfeldt Jakob Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	1.0	2	0.2
Encephalitis (Viral)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	1	0.1
Group A Streptococcal Disease Invasive	0	0.0	2	5.9	0	0.0	0	0.0	2	1.1	5	1.7	7	3.5	16	1.7
Group B Streptococcal Disease of the Newborn	2	24.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.2
Influenza (Laboratory Confirmed)	14	168.7	27	79.5	32	32.6	12	9.6	25	14.1	36	12.4	116	57.6	262	28.1
Meningitis (Other Bacterial)	0	0.0	0	0.0	0	0.0	2	1.6	1	0.6	1	0.3	1	0.5	5	0.5
Meningitis (Viral)	2	24.1	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	3	0.3
Meningococcal Disease Invasive	1	12.1	2	5.9	1	1.0	2	1.6	0	0.0	2	0.7	0	0.0	8	0.9
Methicillin resistant Staphylococcus aureus	7	84.4	3	8.8	9	9.2	34	27.3	65	36.7	137	47.3	758	376.5	1013	108.6
Pneumococcal Disease Invasive	0	0.0	2	5.9	1	1.0	0	0.0	0	0.0	4	1.4	7	3.5	14	1.5
Tuberculosis	0	0.0	0	0.0	0	0.0	0	0.0	3	1.7	0	0.0	1	0.5	4	0.4
Vancomycin resistant Enterococcus	0	0.0	0	0.0	0	0.0	0	0.0	3	1.7	6	2.1	22	10.9	31	3.3
<b>Bloodborne and Sexually Transmitted</b>																
Chlamydia	0	0.0	0	0.0	14	14.3	1494	1199.8	478	270.0	40	13.8	2	1.0	2033*	217.9
Gonorrhea	0	0.0	0	0.0	1	1.0	83	66.7	44	24.9	14	4.8	1	0.5	143	15.3
Hepatitis B (acute)	0	0.0	0	0.0	1	1.0	2	1.6	2	1.1	2	0.7	0	0.0	7	0.8
Hepatitis B (chronic)	0	0.0	1	2.9	0	0.0	2	1.6	8	4.5	3	1.0	0	0.0	14	1.5
Hepatitis C	0	0.0	0	0.0	1	1.0	47	37.7	107	60.4	114	39.3	10	5.0	281*	30.1
HIV	0	0.0	0	0.0	0	0.0	0	0.0	9	5.1	5	1.7	0	0.0	14	1.5
Syphilis	0	0.0	0	0.0	0	0.0	0	0.0	6	3.4	2	0.7	4	2.0	12	1.3
<b>Vectorborne and Zoonoses</b>																
Lyme Disease	0	0.0	0	0.0	1	1.0	2	1.6	1	0.6	3	1.0	6	3.0	13	1.4
Malaria	0	0.0	0	0.0	1	1.0	1	0.8	0	0.0	0	0.0	0	0.0	2	0.2
Q-Fever	0	0.0	0	0.0	0	0.0	0	0.0	6	3.4	11	3.8	0	0.0	17	1.8
Toxoplasmosis	0	0.0	0	0.0	0	0.0	1	0.8	1	0.6	1	0.3	0	0.0	3	0.3
West Nile Virus	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	1	0.1
<b>Vaccine Preventable</b>																
Haemophilus influenzae type b (Hib) Invasive Disease	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	1	0.1
Mumps	0	0.0	0	0.0	0	0.0	0	0.0	5	2.8	0	0.0	0	0.0	5	0.5
Pertussis	3	36.2	1	2.9	4	4.1	2	1.6	2	1.1	2	0.7	0	0.0	14	1.5
<b>Total</b>	<b>31</b>	<b>373.6</b>	<b>58</b>	<b>170.9</b>	<b>90</b>	<b>91.7</b>	<b>1752</b>	<b>1407.0</b>	<b>867</b>	<b>489.8</b>	<b>533</b>	<b>183.9</b>	<b>1034</b>	<b>513.6</b>	<b>4372</b>	<b>468.5</b>

\*Five cases of chlamydia and two cases of Hepatitis C with age unspecified.